RHOD

Across TCGA pan-cancer cohorts, RHOD mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RHOD data layer compared with 24 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RHOD mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RHOD expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC and HNSC are the cancer types where RHOD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.646	0.261	.003	24	view →
HNSC	DFS	Median	All	0.743	0.556	.017	14	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RHOD–PDAC (DFS)

Open the PDAC breakdown →